Abstract
Lung cancer is the most common cause of cancer-related death worldwide, owing to its metastatic spread at the time of diagnosis. As a result, chemotherapy is the standard of care for the majority of patients. In recent years, the role of chemotherapy has expanded to include maintenance therapy and approved second-and third-line treatments. Nonetheless, traditional chemotherapy has modestly improved outcomes in patients with advanced non-small-cell lung cancer (NSCLC). Research efforts have been redirected toward the integration of molecularly-targeted agents into a treatment algorithm with unprecedented survival rates in selected patients. This article will provide an update on the multiple systemic regimens available to treat NSCLC, and discuss emerging molecular-based therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 629-639 |
Number of pages | 11 |
Journal | Clinical Advances in Hematology and Oncology |
Volume | 11 |
Issue number | 10 |
State | Published - Oct 2013 |
Keywords
- Chemotherapy
- Maintenance therapy
- Molecularly targeted therapy
- Non-small-cell lung cancer
ASJC Scopus subject areas
- Oncology
- Hematology